119 related articles for article (PubMed ID: 23475216)
41. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes.
Tremblay N; Fontaine P; Perreault C
Transplantation; 1994 Jul; 58(1):59-67. PubMed ID: 8036709
[TBL] [Abstract][Full Text] [Related]
42. Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.
Ofran Y; Kim HT; Brusic V; Blake L; Mandrell M; Wu CJ; Sarantopoulos S; Bellucci R; Keskin DB; Soiffer RJ; Antin JH; Ritz J
Clin Cancer Res; 2010 Mar; 16(5):1642-51. PubMed ID: 20160060
[TBL] [Abstract][Full Text] [Related]
43. Specific T Cell Responses against Minor Histocompatibility Antigens Cannot Generally Be Explained by Absence of Their Allelic Counterparts on the Cell Surface.
Bijen HM; Hassan C; Kester MGD; Janssen GMC; Hombrink P; de Ru AH; Drijfhout JW; Meiring HD; de Jong AP; Falkenburg JHF; Jimenez CR; Heemskerk MHM; van Veelen PA
Proteomics; 2018 Jun; 18(12):e1700250. PubMed ID: 29251415
[TBL] [Abstract][Full Text] [Related]
44. Minor histocompatibility antigens as risk factor for poor prognosis in kidney transplantation.
Pabón MA; Navarro CE; Martin R; Rodríguez M; Martin I; Gaitán L; Gómez A; Lozano E
Transplant Proc; 2011 Nov; 43(9):3319-23. PubMed ID: 22099788
[TBL] [Abstract][Full Text] [Related]
45. Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets.
Griffioen M; van Bergen CA; Falkenburg JH
Front Immunol; 2016; 7():100. PubMed ID: 27014279
[TBL] [Abstract][Full Text] [Related]
46. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations.
Nielsen M; Lundegaard C; Worning P; Lauemøller SL; Lamberth K; Buus S; Brunak S; Lund O
Protein Sci; 2003 May; 12(5):1007-17. PubMed ID: 12717023
[TBL] [Abstract][Full Text] [Related]
47. Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors.
Mei S; Ayala R; Ramarathinam SH; Illing PT; Faridi P; Song J; Purcell AW; Croft NP
Mol Cell Proteomics; 2020 Jul; 19(7):1236-1247. PubMed ID: 32357974
[TBL] [Abstract][Full Text] [Related]
48. Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptide-HLA Interactions.
Bassani-Sternberg M; Gfeller D
J Immunol; 2016 Sep; 197(6):2492-9. PubMed ID: 27511729
[TBL] [Abstract][Full Text] [Related]
49. Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens.
Fuchs KJ; van de Meent M; Honders MW; Khatri I; Kester MGD; Koster EAS; Koutsoumpli G; de Ru AH; van Bergen CAM; van Veelen PA; 't Hoen PAC; van Balen P; van den Akker EB; Veelken JH; Halkes CJM; Falkenburg JHF; Griffioen M
Blood; 2024 May; 143(18):1856-1872. PubMed ID: 38427583
[TBL] [Abstract][Full Text] [Related]
50. The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands.
Gfeller D; Guillaume P; Michaux J; Pak HS; Daniel RT; Racle J; Coukos G; Bassani-Sternberg M
J Immunol; 2018 Dec; 201(12):3705-3716. PubMed ID: 30429286
[TBL] [Abstract][Full Text] [Related]
51. Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers.
Granados DP; Rodenbrock A; Laverdure JP; Côté C; Caron-Lizotte O; Carli C; Pearson H; Janelle V; Durette C; Bonneil E; Roy DC; Delisle JS; Lemieux S; Thibault P; Perreault C
Leukemia; 2016 Jun; 30(6):1344-54. PubMed ID: 26857467
[TBL] [Abstract][Full Text] [Related]
52. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
Bassani-Sternberg M; Pletscher-Frankild S; Jensen LJ; Mann M
Mol Cell Proteomics; 2015 Mar; 14(3):658-73. PubMed ID: 25576301
[TBL] [Abstract][Full Text] [Related]
53. Naturally processed non-canonical HLA-A*02:01 presented peptides.
Hassan C; Chabrol E; Jahn L; Kester MG; de Ru AH; Drijfhout JW; Rossjohn J; Falkenburg JH; Heemskerk MH; Gras S; van Veelen PA
J Biol Chem; 2015 Jan; 290(5):2593-603. PubMed ID: 25505266
[TBL] [Abstract][Full Text] [Related]
54. HLA class I-restricted T cell epitopes isolated and identified from myeloid leukemia cells.
Nyambura LW; Muñoz AA; le Coutre P; Walden P
Sci Rep; 2019 Oct; 9(1):14029. PubMed ID: 31575892
[TBL] [Abstract][Full Text] [Related]
55. Direct identification of HLA class I and class II-restricted T cell epitopes in pancreatic cancer tissues by mass spectrometry.
Fujiwara K; Shao Y; Niu N; Zhang T; Herbst B; Henderson M; Muth S; Zhang P; Zheng L
J Hematol Oncol; 2022 Oct; 15(1):154. PubMed ID: 36284347
[TBL] [Abstract][Full Text] [Related]
56. Characteristics of HLA-E Restricted T-Cell Responses and Their Role in Infectious Diseases.
Joosten SA; Sullivan LC; Ottenhoff TH
J Immunol Res; 2016; 2016():2695396. PubMed ID: 27699181
[TBL] [Abstract][Full Text] [Related]
57. HSPVdb--the Human Short Peptide Variation Database for improved mass spectrometry-based detection of polymorphic HLA-ligands.
Nijveen H; Kester MG; Hassan C; Viars A; de Ru AH; de Jager M; Falkenburg JH; Leunissen JA; van Veelen PA
Immunogenetics; 2011 Mar; 63(3):143-53. PubMed ID: 21125265
[TBL] [Abstract][Full Text] [Related]
58. Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis.
Overes IM; Levenga TH; Vos JC; van Horssen-Zoetbrood A; van der Voort R; De Mulder PH; de Witte TM; Dolstra H
Cancer Immunol Immunother; 2009 Mar; 58(3):429-39. PubMed ID: 18719914
[TBL] [Abstract][Full Text] [Related]
59. Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies.
Ghosh M; Gauger M; Marcu A; Nelde A; Denk M; Schuster H; Rammensee HG; Stevanović S
Mol Cell Proteomics; 2020 Mar; 19(3):432-443. PubMed ID: 31937595
[TBL] [Abstract][Full Text] [Related]
60. Mass Spectrometry Based Immunopeptidomics Leads to Robust Predictions of Phosphorylated HLA Class I Ligands.
Solleder M; Guillaume P; Racle J; Michaux J; Pak HS; Müller M; Coukos G; Bassani-Sternberg M; Gfeller D
Mol Cell Proteomics; 2020 Feb; 19(2):390-404. PubMed ID: 31848261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
